[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"endometrial-adenocarcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:endometrial-adenocarcinoma":34},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,63,97,125,152,183,203,232,260,287],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":41,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":62},"100644985","clonal-hematopoiesis-chemotherapy-and-radiation-effects-study-100644985",false,"NCT07675967","Clonal Hematopoiesis Chemotherapy and Radiation Effects Study","CH CARE","Inclusion Criteria:\n\n* Participants to be included in this study include the following:\n* Adults age \\>18 years\n* Diagnosed with solid malignancy (breast, ovarian, lung, gastric, colorectal, esophageal, uterine, head and neck, or sarcoma cancers)\n* Have a pending plan to receive chemotherapy or radiation for their solid malignancy (cancer).\n* Has not received cytotoxic chemotherapy or radiation for their solid cancer diagnosis in the past.\n\nExclusion Criteria:\n\n* Individuals without plans for cytotoxic chemotherapy, radiation or PARP inhibitor exposure\n* Individuals who have received prior chemotherapy and or radiation for their current solid malignancy (cancer)\n* Individuals with any prior history of blood cancer (leukemia, myelodysplastic syndrome, lymphoma, multiple myeloma, including smoldering multiple myeloma). Persons with blood cancer precursors including clonal hematopoiesis of indeterminate potential (CHIP), clonal cytopenia of uncertain significance (CCUS), monoclonal B lymphocytosis (MBL), monoclonal gammopathy of uncertain significance (MGUS) are eligible for study participation.","ALL","18 Years",{"count":19,"type":20},5000,"ESTIMATED","OBSERVATIONAL","The goal of the Clonal Hematopoiesis Chemotherapy and Radiation Effects (CH CARE) Study is to understand how the presence or absence of clonal hematopoiesis (CH) influences outcomes in people receiving chemotherapy and radiation for solid cancers.\n\nThe study will collect biospecimens and clinical information. These data will be used to define clinical and molecular features that predict the presence of high-risk clonal hematopoiesis (CH) in patients exposed to cytotoxic anti-cancer therapy. Predictive features will be utilized to identify populations of cancer patients and survivors who are at the highest risk of developing therapy-related myeloid neoplasms (t-MNs).\n\nUltimately this study will result in the development of a novel novel risk prediction algorithm for t-MNs in patients with solid cancers and drive potential therapeutic approaches to intercept progression from CH to often fatal t-MNs.",[24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40],"Lung Cancer (Diagnosis)","Osteochondroma","Spitz Nevus","Solid Cancers","Breast Cancer","Gastric (Stomach) Cancer","Colorectal (Colon or Rectal) Cancer","Sarcoma","Ovarian Adenocarcinoma","Uterine Adenocarcinoma","Endometrial Adenocarcinoma","Esophageal Adenocarcinoma","Head and Neck Cancer","Therapy-Related Acute Myeloid Leukemia","Therapy-Related MDS","Clonal Hematopoiesis of Indeterminate Potential (CHIP)","Clonal Cytopenia of Undetermined Significance",[42,43,44,45,46,47,48,49],"Adult cancer survivors","Precursor Lesions","clonal hematopoiesis","chemotherapy","radiation","therapy-related myeloid neoplasms","CCUS","clonal hematopoiesis of indeterminate potential","RECRUITING","2026-06-29",{"date":53,"type":54},"2026-06-30","ACTUAL",{"date":56,"type":54},"2025-04-04",{"date":58,"type":20},"2035-03-31",{"name":60,"class":61},"Dana-Farber Cancer Institute","OTHER",1,{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":70,"minAge":17,"maxAge":4,"enrollmentInfo":71,"targetDuration":4,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":4,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":96},"100447912","phase-2-testing-nivolumab-with-or-without-ipilimumab-in-deficient-mismatch-repair-system-dmmr-recurrent-endometrial-carcinoma-100447912","NCT05112601","Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma","A Randomized Phase II Trial of Nivolumab and Ipilimumab Compared to Nivolumab Monotherapy in Patients With Deficient Mismatch Repair System Recurrent Endometrial Carcinoma","Inclusion Criteria:\n\n* Patients with measurable or non-measurable (detectable) recurrent endometrial cancer\n* Measurable disease will be defined and monitored by RECIST v 1.1. Measurable disease is defined per RECIST 1.1 criteria as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded). Each lesion must be \\>= 10 mm when measured by computed tomography (CT) or magnetic resonance imaging (MRI). Lymph nodes must be \\>= 15 mm in short axis when measured by CT or MRI\n* Non-measurable (detectable) disease in a patient is defined in this protocol per RECIST 1.1 criteria as one who does not have measurable disease but has at least one of the following conditions:\n\n  * All other lesions (or sites of disease), including small lesions (longest diameter \\\u003C10 mm or pathological lymph nodes with \\>= 10 to \\\u003C 15 mm short axis), are considered non-measurable disease\n  * Ascites and\u002For pleural effusion attributed to tumor\n  * Solid and\u002For cystic abnormalities on radiographic imaging that do not meet RECIST 1.1 definitions for target lesions\n* Patients must have endometrial cancer with deficient mismatch repair system. All patients must have institutional immunohistochemistry (IHC) and\u002For microsatellite instability (MSI) testing to determine mismatch repair (MMR) status. MMR deficiency is defined as lack of expression of one or more mismatch repair proteins (MLH1, PMS2, MSH2, MSH6, EPCAM) by immunohistochemistry and\u002For presence of microsatellite instability high using the National Cancer Institute (NCI)-5plex and Promega v1.2 assays, or institutional standards (e.g. next-generation sequencing \\[NGS\\] panel)\n\n  * Method(s) of detection of MMR deficiency will be recorded for each patient. An institutional pathology report, and additional reports if available, documenting these results must be submitted. Patients with \"equivocal\" results on MMR testing by immunohistochemistry may be eligible if they have documented evidence of microsatellite instability by MSI testing or by next generation sequencing assays. MMR testing by IHC may be used to resolve equivocal\u002Findeterminate MSI results\n* Histologic confirmation of the original primary tumor is required (submission of pathology report(s) is required). Patients with the following histologic types are eligible: Endometrioid adenocarcinoma, mucinous adenocarcinoma, dedifferentiated\u002Fundifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, adenocarcinoma not otherwise specified (N.O.S.)\n* Patients may have received 1-2 prior lines of systemic therapy:\n\n  * Prior anti-PD1\u002FPD-L1 therapy is allowed if given in combination with chemotherapy or radiation therapy in adjuvant or primary metastatic\u002Frecurrent settings. Patients must have had a complete response and have disease progression\u002Frelapse with treatment-free interval of 12 months or more from last dose of therapy with immune check inhibition\n* Patients may have received prior radiation therapy for treatment of endometrial cancer. Prior radiation therapy may have included pelvic radiation therapy, extended field pelvic\u002Fpara aortic radiation therapy, intravaginal brachytherapy, and\u002For palliative radiation therapy. All radiation therapy must be completed at least 4 weeks prior to registration\n* Patients may have received prior hormonal therapy for treatment of endometrial cancer. All hormonal therapy must be discontinued at least three weeks prior to registration\n* Any other prior therapy directed at the malignant tumor including chemotherapy, targeted agents, biologic agents, immunologic agents, and any investigational agents, must be discontinued at least 4 weeks prior to registration (6 weeks for nitrosoureas or mitomycin C)\n* Age \\>= 18\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2\n* Platelets \\>= 100,000\u002Fmcl\n* Absolute neutrophil count (ANC) \\>= 1,500\u002Fmcl\n* Creatinine =\\\u003C 1.5 x institutional\u002Flaboratory upper limit of normal (ULN)\n* Total serum bilirubin level =\\\u003C 1.5 x ULN (patients with known Gilbert's disease who have bilirubin level =\\\u003C3 x ULN may be enrolled)\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\\\u003C 3 x ULN\n* Adequate oxygen saturation via pulse oximeter (CTCAE v.5.0 hypoxia \\\u003C grade 2 within 28 days prior to registration)\n* Thyroid-stimulating hormone (TSH) within normal limits (TSH \\\u003C ULN allowed in euthyroid patients on thyroid replacement therapy). TSH testing is only required if clinically indicated\n* Patients must have recovered from effects of recent surgery, radiotherapy or chemotherapy. At least 4 weeks must have elapsed since major surgery\n* As clinically indicated, patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better and have a corrected QT (QTc) interval \\\u003C 450 msec\n* The effects of nivolumab, and ipilimumab on the developing human fetus are unknown. For this reason and because nivolumab and ipilimumab are known to be teratogenic, women of child-bearing potential (WOCBP) must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for 5 months after the last dose of investigational drug. Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU\u002FL or equivalent units of human chorionic gonadotropin \\[HCG\\]) within 24 hours prior to the start of nivolumab. Women must not be breastfeeding. Women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile) do not require contraception\n\n  * WOCBP is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes. In addition, women under the age of 55 must have a documented serum follicle stimulating hormone (FSH) level less than 40 mIU\u002FmL\n* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial\n* Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of registration are eligible for this trial\n* Patients with evidence of chronic hepatitis B virus (HBV) infection must have an undetectable HBV viral load on suppressive therapy, if indicated\n* Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load\n* Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression and the patient is stable off steroids for at least one month\n* The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the United States (U.S.), authorization permitting release of personal health information\n* Patients with vitiligo, endocrine deficiencies including thyroiditis managed with replacement hormones including physiologic corticosteroids are eligible\n* Patients with rheumatoid arthritis and other arthropathies, Sjogren's syndrome and psoriasis controlled with topical medication and patients with positive serology, such as antinuclear antibodies (ANA), anti-thyroid antibodies should be evaluated for the presence of target organ involvement and potential need for systemic treatment but should otherwise be eligible\n\nExclusion Criteria:\n\n* Patients with a diagnosis of endometrial serous carcinoma or carcinosarcoma\n* Patients who received prior anti-PD1\u002FPD-L1 therapy and had grade 3-4 or recurring grade 2 immune-related toxicities that led to dose delay or discontinuation of immunotherapy due to those toxicities\n* Patients who received anti-CTLA-4 therapy or other immunotherapeutic agents\n* Patients on chronic steroid therapy except those on replacement therapy at a daily dose of 10mg or less prednisone or equivalent\n* Patients on immunosuppressive therapy, with the exception of:\n\n  * Intra-nasal, inhaled, topical or local steroid injections\n  * Premedication for hypersensitivity reaction\n* Patients with active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids, should be excluded. These include but are not limited to patients with a history of immune related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as systemic lupus erythematosus (SLE), connective tissue diseases, scleroderma, inflammatory bowel disease (IBD), Crohn's, ulcerative colitis, hepatitis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome should be excluded because of the risk of recurrence or exacerbation of disease\n* Patients with known immune impairment who may be unable to respond to anti-CTLA-4 antibody\n* Patients with uncontrolled intercurrent illness including, but not limited to: ongoing or active infection (except for uncomplicated urinary tract infection), interstitial lung disease or active, non-infectious pneumonitis, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* Women who are pregnant or unwilling to discontinue nursing\n* Prior therapy with CTLA-4 inhibitors, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab, and\u002For ipilimumab including severe hypersensitivity reactions to any monoclonal antibody","FEMALE",{"count":72,"type":20},81,"INTERVENTIONAL",[75],"PHASE2","This phase II trial tests whether the combination of nivolumab and ipilimumab is better than nivolumab alone to shrink tumors in patients with deficient mismatch repair system (dMMR) endometrial carcinoma that has come back after a period of time during which the cancer could not be detected (recurrent). Deoxyribonucleic acid (DNA) mismatch repair (MMR) is a system for recognizing and repairing damaged DNA. In 2-3% of endometrial cancers this may be due to a hereditary condition resulted from gene mutation called Lynch Syndrome (previously called hereditary nonpolyposis colorectal cancer or HNPCC). MMR deficient cells usually have many DNA mutations. Tumors that have evidence of mismatch repair deficiency tend to be more sensitive to immunotherapy. There is some evidence that nivolumab with ipilimumab can shrink or stabilize cancers with deficient mismatch repair system. However, it is not known whether this will happen in endometrial cancer; therefore, this study is designed to answer that question. Monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving nivolumab in combination with ipilimumab may be better than nivolumab alone in treating dMMR recurrent endometrial carcinoma.",[34,78,79,80,81,82,83,84,85],"Endometrial Clear Cell Adenocarcinoma","Endometrial Dedifferentiated Carcinoma","Endometrial Endometrioid Adenocarcinoma","Endometrial Mixed Cell Adenocarcinoma","Endometrial Mucinous Adenocarcinoma","Endometrial Undifferentiated Carcinoma","Endometrioid Adenocarcinoma","Recurrent Endometrial Carcinoma","2026-06-18",{"date":88,"type":54},"2026-06-22",{"date":90,"type":54},"2022-06-02",{"date":92,"type":20},"2032-07-30",{"name":94,"class":95},"National Cancer Institute (NCI)","NIH",137,{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":70,"minAge":17,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":73,"phases":106,"briefSummary":107,"conditions":108,"keywords":109,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":124},"100481384","phase-2-a-phase-2-study-of-acr-368-in-endometrial-adenocarcinoma-100481384","NCT05548296","A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma","A Phase 2 Study of ACR-368 Therapy in Subjects With Endometrial Cancer","Inclusion Criteria: General\n\n1. Participant must be able to give signed, written informed consent.\n2. Participant must have histologically documented, high-grade endometrial cancer.\n\n   Arms 1 and 2\n   1. All high-grade epithelial endometrial histological subtypes are eligible including: endometrioid (all Grade 3), serous, carcinosarcomas, clear-cell carcinoma, and mixed histologies.\n\n      Note: Subjects with p53 mutant Grade 2 endometrioid cancer are eligible\n\n      Arms 3 and 4\n   2. Serous carcinoma or mixed tumors with a majority component of serous carcinoma or carcinosarcoma where the carcinomatous component is serous carcinoma.\n3. Treatment History Requirements:\n\n   Arms 1 and 2\n   1. Subject must have received prior platinum-based chemotherapy\n   2. Subject must have received prior anti-PD-(L)1 therapy\n   3. Subject must not have received more than three lines of prior systemic therapy Arms 3 and 4\n\n   \u003C!-- -->\n\n   1. Subject must have received prior platinum-based chemotherapy\n   2. Subject must have received prior anti-PD-(L)1 therapy\n   3. Subject must not have received more than two lines of prior systemic therapy\n4. Participant must have histologically confirmed metastatic cancer that has progressed during or after at least 1 prior therapeutic regimen.\n5. Participant must have at least 1 measurable lesion per RECIST v1.1 criteria (by local Investigator) in a baseline tumor imaging that has been obtained within 28 days of the treatment start. Participant must have radiographic evidence of disease progression based on RECIST v1.1 criteria following the most recent line of treatment.\n6. Arm 1 and 2 only: Participant must be willing to provide tissue from a newly obtained tumor biopsy from an accessible tumor lesion not previously irradiated after written informed consent.\n\n   Newly obtained is defined as a specimen taken after written informed consent is obtained, during the 28-day Screening period.\n\n   Note: Subjects at EU sites are not eligible for Arm 1 and Arm 2\n7. For all subjects participating in Arm 3 and 4, archival tumor tissue must be provided either during or after screening either as a tissue block or at least 20 unstained slides.\n8. Participant must have stabilized or recovered (Grade 1 or baseline) from all prior therapy related toxicities, except as follows:\n\n   1. Alopecia is accepted.\n   2. Endocrine events from prior immunotherapy stabilized at ≤ Grade 2 due to need for replacement therapy are accepted (including hypothyroidism, diabetes mellitus, or adrenal insufficiency).\n   3. Neuropathy events from prior cytotoxic therapies stabilized at ≤ Grade 2 are accepted.\n9. Participant must have an Eastern Cooperative Oncology Group Performance Status 0 or 1.\n10. Participant must have an estimated life expectancy of longer than 3 months in the clinical judgment of the investigator.\n11. Participant must have adequate organ function at Screening, defined as:\n\n    1. Absolute neutrophil count \\> 1500 cells\u002FµL without growth factor support within 2 weeks prior to obtaining the hematology values at Screening.\n    2. Hemoglobin ≥ 9.0 g\u002FdL.\n    3. Platelets ≥ 150,000 cells\u002FµL without transfusion within 1 week prior to obtaining the hematology values at Screening.\n    4. Renal function is defined as Glomerular filtration rate (GFR) ≥ 50 mL\u002Fmin\u002F1.73m2. Note: GFR may be estimated using site standard methods (e.g., CKD-EPI, MDRD, or Cockcroft-Gault) or measured using 24-hour urine collection or Chrome-EDTA clearance, as per site standard practice.\n    5. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 × upper limit of normal (ULN); ≤ 5 × ULN if liver metastases are present.\n    6. Total bilirubin ≤ 1.5 × ULN not associated with Gilbert's syndrome. If associated with Gilbert's syndrome ≤ 3 x ULN is acceptable.\n    7. Serum albumin ≥ 3 g\u002FdL.\n12. Participant must have adequate coagulation profile as defined below if not on anticoagulation. If subject is receiving anticoagulation therapy, then subject must be on a stable dose of anticoagulation for ≥ 1 month:\n\n    1. Prothrombin time within 1.5 x ULN.\n    2. Activated partial thromboplastin time within 1.5 x ULN.\n\nExclusion Criteria: General\n\n1. Participant with known symptomatic brain metastases requiring \\> 10 mg\u002Fday of prednisolone (or its equivalent). Participants with previously diagnosed brain metastases are eligible if they have completed their treatment, have recovered from the acute effects of radiation therapy or surgery prior to the start of ACR-368 treatment, fulfill the steroid requirement for these metastases, and are neurologically stable based on central nervous system imaging ≥ 4 weeks after treatment.\n2. Participant has mesenchymal tumors of the uterus.\n3. Participant has a history of clinically meaningful ascites, defined as history of paracentesis or thoracentesis with therapeutic intent, within 4 weeks of Screening. Subjects with planned therapeutic paracentesis or thoracentesis between Screening and Cycle 1 Day 1 dosing are excluded.\n4. Participant had systemic therapy or radiation therapy within 3 weeks prior to the first dose of study drug.\n5. Participants has known human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection that is considered uncontrolled based on the criteria included in Appendix 2.\n6. Participant has a history of clinically meaningful coagulopathy, bleeding diathesis.\n7. Participant has cardiovascular disease, defined as:\n\n   1. Uncontrolled hypertension defined as blood pressure \\> 160\u002F90 mmHg at Screening confirmed by repeat (medication permitted).\n   2. History of torsades de pointes, significant Screening electrocardiogram (ECG) abnormalities, including ventricular rhythm disturbances, unstable cardiac arrhythmia requiring medication, pathologic symptomatic bradycardia, left bundle branch block, second degree atrioventricular (AV) block type II, third degree AV block, Grade ≥ 2 bradycardia, uncorrected hypokalemia not amenable to correction, congenital long QT syndrome, prolonged QT interval due to medications, corrected QT based on Fridericia's formula (QTcF) \\> 450 msec (for men) or \\> 470 msec (for women).\n   3. Symptomatic heart failure (per New York Heart Association guidelines; (Caraballo, 2019), unstable angina, myocardial infarction, severe cardiovascular disease (ejection fraction \\\u003C 20%, transient ischemic attack, or cerebrovascular accident within 6 months of Day 1).\n8. Participant has a history of major surgery within 4 weeks of Screening.\n9. Participant has experienced bowel obstruction related to the current cancer within the last 4 weeks or signs or symptoms of intestinal obstruction, which include nausea, vomiting, or objective radiologic finding of bowel obstruction in the last 4 weeks before the start of the treatment.\n10. Participant has taken a prior cell cycle CHK1 inhibitor, including ACR-368",{"count":105,"type":20},350,[75],"This is an open label Phase 2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or with ultra-low dose gemcitabine (ULDG) sensitization in participants with endometrial cancer.",[34],[110,111,112,113],"Endometrial Cancer","Endometrial Neoplasm","Ultralow dose gemcitabine","ACR-368","2026-06-12",{"date":116,"type":54},"2026-06-15",{"date":118,"type":54},"2022-08-29",{"date":120,"type":20},"2027-11-30",{"name":122,"class":123},"Acrivon Therapeutics","INDUSTRY",91,{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":70,"minAge":17,"maxAge":4,"enrollmentInfo":133,"targetDuration":135,"studyType":21,"phases":4,"briefSummary":136,"conditions":137,"keywords":138,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":62},"100638221","comparison-of-sentinel-lymph-node-applications-in-endometrial-cancer-cases-performed-with-vaginal-natural-orifice-transluminal-endoscopic-surgery-v-notes-and-conventional-laparoscopy-100638221","NCT07583329","Comparison of Sentinel Lymph Node Applications in Endometrial Cancer Cases Performed With Vaginal Natural Orifice Transluminal Endoscopic Surgery (V-NOTES) and Conventional Laparoscopy","Comparison of Sentinel Lymph Node Applications in Endometrial Cancer Cases Performed With V-NOTES and Conventional Laparoscopy: A Multicenter Prospective Observational Study","V-COSMOS","Inclusion Criteria:\n\n* Age ≥18 years\n* Histologically confirmed endometrial cancer on preoperative endometrial biopsy\n* Disease confirmed to be confined to the uterus based on clinical evaluation and imaging\n* No evidence of lymphatic or distant metastasis on positron emission tomography\u002Fcomputed tomography(PET\u002FCT) or magnetic resonance imaging (MRI)\n* Surgical staging with sentinel lymph node biopsy recommended by a multidisciplinary tumor board\n* Surgical treatment performed using either conventional laparoscopy or the vNOTES approach\n\nExclusion Criteria:\n\n* Presence of extrauterine disease\n* Detection of distant metastasis\n* Surgery performed via an open (laparotomy) approach\n* Incomplete medical records\n* History of prior pelvic radiotherapy",{"count":134,"type":20},160,"10 Years","Endometrial cancer is a common cancer in women, and surgery is usually the first step in treatment. During surgery, doctors often check nearby lymph nodes to see if the cancer has spread. A newer method called sentinel lymph node (SLN) mapping allows doctors to examine only the first few lymph nodes most likely to contain cancer. This can reduce the need for removing many lymph nodes and may lower the risk of complications.\n\nMinimally invasive surgery is commonly performed using small abdominal incisions (laparoscopy). A newer technique, called vaginal natural orifice transluminal endoscopic surgery (vNOTES), allows the surgery to be performed through the vagina without any cuts on the abdomen. This approach may lead to less pain, quicker recovery, and no visible scars.\n\nThis study will compare these two surgical methods-laparoscopy and vNOTES-in patients with early-stage endometrial cancer. Researchers will look at how safe and effective each method is, how patients recover after surgery, and how well the sentinel lymph node procedure works with each technique. The study will also examine how quickly surgeons become experienced with the newer vNOTES method.\n\nThe goal of this research is to determine whether vNOTES can be a safe and effective alternative to standard laparoscopic surgery, while offering potential benefits for patients.",[34,110],[139,140,141],"v-notes","sentinel lymph node","conventional laparoscopy","NOT_YET_RECRUITING","2026-05-18",{"date":145,"type":54},"2026-05-20",{"date":147,"type":20},"2026-05-19",{"date":149,"type":20},"2036-04-30",{"name":151,"class":61},"Cukurova University",{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":73,"phases":161,"briefSummary":163,"conditions":164,"keywords":4,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":182},"100546807","phase-1-a-study-to-investigate-apl-5125-in-adults-with-advanced-solid-tumors-100546807","NCT06399757","A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors","A Phase 1\u002F2 Study to Assess the Safety and Antitumor Activity of APL-5125 in Adults With Selected Advanced Solid Tumors","Inclusion Criteria:\n\n* 18 years or older\n* Phase 1: Histologically confirmed locally advanced, inoperable, or metastatic tumor; Colorectal carcinoma, Cholangiocarcinoma, Appendiceal adenocarcinoma.\n* For Phase 1 sub-studies: Colorectal carcinoma, Cholangiocarcinoma, Appendiceal adenocarcinoma, Pancreatic Adenocarcinoma, Gastric Adenocarcinoma, Endometrial Adenocarcinoma, Triple Negative Breast Cancer, Ovarian Cancer, Prostate Cancer\n* Phase 2: Colorectal carcinoma\n* No available standard of care therapy or participant is ineligible for standard of care therapy, except in CRC tumor type in which participant must have previously received all the following therapeutic agents:\n\n  * fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy\n  * an anti-VEGF therapy\n  * if wt-RAS (wt-KRAS and wt-NRAS), an anti-EGFR therapy\n* Eastern Cooperative Oncology Group (ECOG) ≤1\n* Body Weight ≥40 kg.\n* Female participants of childbearing potential must have negative serum pregnancy test at screening; must not plan to become pregnant or have ova harvested or breastfeed while on study; must be willing to use specific contraception or avoid intercourse\n* Male participants must be willing to use specific contraception and not plan to impregnate a female partner or donate sperm while on study\n* Participant must be willing and able to provide written informed consent and to comply with the requirements of the trial\n\nExclusion Criteria:\n\n* Certain medical conditions such as: active brain metastases, carcinomatous meningitis, unstable angina pectoris, myocardial infarction or clinically significant ventricular arrhythmias, symptomatic congestive heart failure, uncontrolled active infection, history of significant hemorrhage within 4 weeks of the first dose date, intestinal disease or major gastric surgery, arterial thrombosis within 6 months of screening\n* Certain prior therapies such as: anti-cancer treatment within 2 weeks of Cycle 1 Day 1, prior radiotherapy within 14 days before screening, active anti-coagulation therapy, over the counter or prescription medications within 14 days or 5 half-lives prior to cycle 1 day 1, herbal medicines and supplements within 14 days\n* Major surgery within 1 month of screening\n* Hemoglobin \\\u003C 9.0 g\u002FdL\n* Absolute neutrophil count \\\u003C 1.5 x 10\\^9\u002FL\n* Platelet count \\\u003C 100 x 10\\^9\u002FL\n* Hepatic function:\n\n  1. Aspartate aminotransferase and\u002For alanine aminotransferase (ALT) \\>3 × upper limit of normal (ULN) (\\>5 x ULN for subjects with liver metastases)\n  2. Total bilirubin \\>1.5 × ULN (except participants with Gilbert's syndrome).\n  3. Albumin \\\u003C 3 g\u002FdL\n* Calculated or measured creatinine clearance of \\\u003C60 mL\u002Fminute calculated using the formula of Cockcroft and Gault (\\[140 - Age\\] × Mass \\[kg\\] \u002F \\[72 × serum creatinine mg\u002FdL\\]). Multiply result by 0.85 if female.\n* Fridericia's corrected QT interval (QTcF) \\>470 msec or a family history of Long QT Syndrome.\n* Cardiac function: Echocardiogram (or MUGA) showing Left Ventricular Ejection Fraction (LVEF) \\\u003C45% at rest\n* Infectious diseases: positive for HIV (unless controlled with active retroviral therapy), hepatitis B and hepatitis C",{"count":160,"type":20},100,[162,75],"PHASE1","This is an open-label, Phase 1\u002F2 study to determine the safety, tolerability, and efficacy of APL-5125 for the treatment of selected locally advanced or metastatic solid tumors with particular focus on Colorectal carcinoma (CRC).",[165,166,167,168,169,34,170,171,172],"Colorectal Cancer","Cholangiocarcinoma","Appendiceal Adenocarcinoma","Pancreatic Adenocarcinoma","Gastric Adenocarcinoma","Triple Negative Breast Cancer","Ovarian Cancer","Prostate Cancer","2026-01-05",{"date":175,"type":54},"2026-01-07",{"date":177,"type":54},"2024-06-18",{"date":179,"type":20},"2027-05",{"name":181,"class":123},"Apollo Therapeutics Ltd",9,{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":70,"minAge":4,"maxAge":4,"enrollmentInfo":190,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":192,"conditions":193,"keywords":4,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":62},"100582326","prognosis-of-mettl-14-in-endometrial-carcinoma-100582326","NCT06861855","Prognosis of METTL-14 in Endometrial Carcinoma","Prognostic Impact of Immunohistochemical Expression of METTL-14 in Endometrial Carcinoma","Inclusion Criteria:\n\n* Cases of type1endometrial carcinoma with:\n\n  1. Hystrectomy operation\n  2. Available full clinical data about patient (age, complaint, findings in clinical examination).\n  3. Full data about previous biopsy and radiology.\n  4. Full data about patient survival, disease progression and history of chemotherapy for three years.\n\nExclusion Criteria:\n\n* 1\\. Any case of type 1 endometrial carcinoma with missing clinical, radiologic or follow up data.\n\n  2\\. Cases with no available H\\&E stained slides or formalin fixed paraffin embedded block.\n\n  3.D\\&C.",{"count":191,"type":20},50,"1. To evaluate immunohistochemical expression of METTL14 in type1 endometrial carcinoma.\n2. To evaluate the correlation between METTL14 expression and clinicopathological parameters of patients with type 1endometrial carcinoma such as tumor grade, lymhovascular invasion, age of pateints, tumor stage, presence of myometrial invasion and presence of cervical stroma affection.\n3. To assess correlation of METTL-14 expression with disease free survival and overall survival.",[110,34],"2025-09-29",{"date":196,"type":54},"2025-09-30",{"date":198,"type":20},"2025-09-27",{"date":200,"type":20},"2026-10",{"name":202,"class":61},"Assiut University",{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":209,"eligibilityCriteria":210,"healthyVolunteers":11,"sex":70,"minAge":17,"maxAge":4,"enrollmentInfo":211,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":212,"conditions":213,"keywords":217,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":62},"100598929","surgical-and-obstetric-outcomes-in-endometrial-adenocarcinoma-and-atypical-endometrial-hyperplasia-with-conservative-treatment-100598929","NCT07077876","Surgical and Obstetric Outcomes in Endometrial Adenocarcinoma and Atypical Endometrial Hyperplasia With Conservative Treatment","Surgical and Obstetric Outcomes in Patients With Endometrial Adenocarcinoma and Atypical Endometrial Hyperplasia Undergoing Conservative Treatment","CHOICE","Inclusion Criteria:\n\n* Female patients aged 18 years or older.\n* Histological diagnosis of endometrial adenocarcinoma (EAC) or atypical endometrial hyperplasia (AEH).\n* Patients who underwent conservative treatment with hysteroscopic resection at the CLASS Hysteroscopy Center, performed by a single experienced surgeon (U.C.).\n* Patients treated conservatively due to medical contraindications to radical surgery (e.g., severe comorbidities).\n* Signed informed consent for participation in the study.\n\nExclusion Criteria:\n\n* Patients with other known causes of infertility.\n* Patients with non-endometrioid histological subtypes of endometrial adenocarcinoma.\n* Patients under 18 years of age.\n* Patients who did not provide informed consent for participation.",{"count":160,"type":20},"This observational study aims to evaluate the obstetric and oncological outcomes of patients diagnosed with endometrial adenocarcinoma (EAC) or atypical endometrial hyperplasia (AEH) who underwent conservative treatment at the CLASS Hysteroscopy Center of Fondazione Policlinico Universitario A. Gemelli IRCCS in Rome. Eligible patients include women who received hysteroscopic surgery and hormonal therapy either to preserve fertility or due to medical contraindications to standard radical surgery. Follow-up lasts 12 months.",[34,214,215,216],"Endometrial Hyperplasia","Fertility Preservation","Conservative Treatment Therapy",[110,218,219,220,221,222],"Atypical Endometrial Hyperplasia","Fertility-Sparing Treatment","Hysteroscopy","Progestin Therapy","Reproductive Outcomes","2025-07-12",{"date":225,"type":54},"2025-07-22",{"date":227,"type":54},"2025-06-20",{"date":229,"type":20},"2026-01-20",{"name":231,"class":61},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":233,"slug":234,"hasResults":11,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":238,"eligibilityCriteria":239,"healthyVolunteers":11,"sex":70,"minAge":17,"maxAge":240,"enrollmentInfo":241,"targetDuration":4,"studyType":73,"phases":243,"briefSummary":244,"conditions":245,"keywords":246,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":62},"100586570","phase-2-ql1706-based-therapy-post-pd-1l1-failure-in-advanced-endometrial-cancer-100586570","NCT06917092","QL1706-Based Therapy Post-PD-1\u002FL1 Failure in Advanced Endometrial Cancer","A Phase II Study to Evaluate the Efficacy and Safety of QL1706 Combination Therapy in Immunotherapy-Pretreated Recurrent or Metastatic Endometrial Cancer","QLPPEC\u002FGOG-003","Inclusion Criteria:\n\n1. Age ≥18 years and ≤70 years.\n2. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.\n3. Recurrent or metastatic endometrial carcinoma, confirmed by pathology or imaging.\n4. At least one measurable tumor lesion according to RECIST v1.1 criteria.\n5. Patients must have received prior anti-PD-1\u002FL1 monoclonal antibody (mAb) therapy with a progression-free survival (PFS) of ≥6 months; however, the last dose of anti-PD-1\u002FL1 mAb must have been administered at least 5 half-lives before the initiation of the current treatment.\n6. Patients who have received prior anti-angiogenic therapy are eligible, provided there is a washout period of at least 5 half-lives before re-administration.\n7. Patients who have failed ≤2 lines of prior systemic therapy are eligible (endocrine therapy is not counted as a line of treatment).\n8. All other anti-tumor therapies must be discontinued at least 4 weeks before treatment initiation. Patients taking hormonal medications require a 30-day washout period.\n9. Laboratory tests during the screening period must demonstrate adequate organ function.\n10. Female subjects of childbearing potential must have a negative serum pregnancy test within 3 days prior to the first dose. If a female subject of childbearing potential engages in sexual activity with a non-sterilized male partner, the subject must use an acceptable and highly effective contraceptive method since screening and must agree to continue such precautions until 6 months after the last dose of the study drug; periodic abstinence and the rhythm method are not acceptable forms of contraception.\n11. Voluntarily sign the informed consent form, understand the nature, purpose, and procedures of the trial, and willingly comply with the trial requirements.\n\nExclusion Criteria:\n\n* 1\\. Previous treatment with PD-1\u002FCTLA-4 dual-target immunotherapy, immune checkpoint agonists (e.g., ICOS, CD40, CD137, GITR, OX40 antibodies, etc.), or immune cell therapy.\n\n  2\\. Discontinuation of anti-PD-1\u002FPD-L1 antibody therapy due to related toxicity. 3. Presence of any active autoimmune disease or history of autoimmune disease (including but not limited to autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hypophysitis, vasculitis, nephritis, hyperthyroidism; patients with vitiligo or childhood asthma that has completely resolved and requires no intervention in adulthood may be included; asthma requiring bronchodilator treatment is excluded).\n\n  4\\. Current use of immunosuppressants or systemic corticosteroids for immunosuppression (dose \\>10 mg\u002Fday prednisone or equivalent) within 2 weeks prior to enrollment.\n\n  5\\. Known active tuberculosis (TB) or suspected active TB requiring clinical evaluation for exclusion; known active syphilis infection.\n\n  6\\. History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.\n\n  7\\. History of severe allergic reactions to monoclonal antibodies. 8. Known history or evidence of interstitial lung disease or active non-infectious pneumonitis.\n\n  9\\. History or current presence of central nervous system (CNS) metastases. Baseline imaging to confirm the absence of brain metastases is not mandatory. Patients with unknown CNS status but clinical signs suggestive of CNS metastases must be excluded via CT\u002FMRI.\n\n  10\\. History of other malignancies (except non-melanoma skin cancer or cervical carcinoma in situ; patients with other prior malignancies must have been disease-free for at least 3 years).\n\n  11\\. Uncontrolled hypertension despite antihypertensive therapy (systolic BP ≥140 mmHg or diastolic BP ≥90 mmHg); hypertensive crisis or hypertensive encephalopathy in the past.\n\n  12\\. History of unstable angina, myocardial infarction (MI), chronic heart failure (CHF), clinically significant arrhythmias requiring treatment (except stable atrial fibrillation), or left ventricular ejection fraction \\\u003C50% within 6 months before the first dose.\n\n  13\\. Current thrombolytic or anticoagulant therapy (prophylactic low-dose aspirin or low molecular weight heparin is permitted).\n\n  14\\. Arterial\u002Fvenous thrombotic events within 6 months before enrollment (e.g., cerebrovascular accident, transient ischemic attack, cerebral hemorrhage, cerebral infarction, deep vein thrombosis, pulmonary embolism).\n\n  15\\. Major vascular disease within 6 months before study treatment (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis).\n\n  16\\. Major surgery within 4 weeks before study treatment (excluding diagnostic procedures) or anticipated major surgery during the study.\n\n  17\\. Prior radiotherapy (except palliative bone radiotherapy), chemotherapy, or surgery (excluding biopsy) within 4 weeks before the first study dose; last antibody dose \\\u003C4 weeks before study treatment; molecular targeted therapy (including other investigational oral targeted agents) \\\u003C5 half-lives before study treatment; or unresolved toxicities (\\>CTCAE grade 1, except alopecia) from prior therapy.\n\n  18\\. Active infection, unexplained fever ≥38.5°C within 7 days before treatment, or baseline white blood cell count \\>15×10⁹\u002FL.\n\n  19\\. Congenital or acquired immunodeficiency (e.g., HIV infection); HBsAg-positive with HBV DNA ≥2000 IU\u002FmL, or HCV antibody-positive.\n\n  20\\. Live\u002Fattenuated vaccination within 4 weeks before study treatment or anticipated during the study.\n\n  21\\. Any other condition deemed by the investigator to potentially affect study results or lead to premature termination.\n\n  22\\. Pregnant or breastfeeding women.","70 Years",{"count":242,"type":20},30,[75],"This is a prospective, single-arm, multicenter Phase II study evaluating the efficacy and safety of QL1706 combined with chemotherapy in patients with advanced recurrent or metastatic endometrial cancer who progressed after prior anti-PD-1\u002FL1 therapy.",[34,110],[247,248,249,250],"Immunotherapy-Pretreated","Recurrent or Metastatic Endometrial Carcinoma","Immune Checkpoint Inhibitors","QL1706","2025-04-01",{"date":253,"type":54},"2025-04-08",{"date":255,"type":20},"2025-05-01",{"date":257,"type":20},"2030-04-30",{"name":259,"class":61},"Tianjin Medical University Cancer Institute and Hospital",{"id":261,"slug":262,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":264,"acronym":265,"eligibilityCriteria":266,"healthyVolunteers":11,"sex":70,"minAge":17,"maxAge":267,"enrollmentInfo":268,"targetDuration":4,"studyType":73,"phases":270,"briefSummary":272,"conditions":273,"keywords":274,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":62},"100489602","personalized-treatment-for-endometrial-carcinoma-100489602","NCT05655260","PErsonalized TReatment for Endometrial Carcinoma","PETREC","Inclusion Criteria:\n\n* Age 18 to 100 years\n* WHO performance status 0 to 2\n* Stage I-II molecular integrated high-intermediate or high-risk endometrial carcinoma\n\nExclusion Criteria:\n\n* Age \\\u003C18 years or \\>100 years\n* WHO performance status \\>2\n* Uterine sarcoma\n* A history of malignancy within 5 years\n* Previous pelvic radiotherapy\n* An interval of \\>30 days between surgery and start of chemotherapy or \\>8 weeks between surgery and start of radiotherapy (longer intervals may be permitted with investigator´s approval)","100 Years",{"count":269,"type":20},300,[271],"NA","The goal of this clinical trial is to compare the efficacy of adjuvant therapies in women with stage I-II molecular integrated high-intermediate or high-risk endometrial carcinoma. Specifically, the invesigators want to compare:\n\n* Chemotherapy vs. chemoradiotherapy in p53 abn subtype and nonendometrioid carcinomas.\n* Vaginal brachytherapy vs. whole pelvic radiotherapy in the MMR-D molecular subgroup.\n* Vaginal brachytherapy vs. whole pelvic radiotherapy in the NSMP molecular subgroup.",[34],[275,276,277],"Endometrial carcinoma","Molecular classification","Adjuvant therapy","2024-12-03",{"date":280,"type":54},"2024-12-06",{"date":282,"type":54},"2022-02-08",{"date":284,"type":20},"2028-12-31",{"name":286,"class":61},"University of Helsinki",{"id":288,"slug":289,"hasResults":11,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":4,"eligibilityCriteria":293,"healthyVolunteers":11,"sex":70,"minAge":17,"maxAge":4,"enrollmentInfo":294,"targetDuration":4,"studyType":73,"phases":296,"briefSummary":297,"conditions":298,"keywords":299,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":4},"100521178","phase-2-cadonilimab-ak104-plus-chemotherapy-in-patients-with-recurrent-or-advanced-endometrial-cancer-100521178","NCT06066216","Cadonilimab (AK104) Plus Chemotherapy in Patients With Recurrent or Advanced Endometrial Cancer","Efficacy and Safety of Cadonilimab (AK104) Plus Chemotherapy in the Treatment of Recurrent or Advanced Endometrial Cancer: a Multicenter, Prospective Phase II Trial","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Patients must have had measurable stage III,IVA or recurrent endometrial cancer,and not suitable for curative radiotherapy or surgery.\n3. All patients were required to have histologic confirmation of the original primary tumor (submission of pathology report(s) is required). Patients with the following histologic types were eligible: Endometrioid adenocarcinoma, serous adenocarcinoma, mucinous adenocarcinoma, dedifferentiated\u002Fundifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, carcinosarcoma, etc.\n4. The subject has not received systematic chemotherapy in the advanced or recurrent disease, but is allowed to receive neoadjuvant therapy, adjuvant therapy (including chemotherapy, radiotherapy, or endocrine therapy) in the initial treatment stage, and the last adjuvant chemotherapy is required to be completed at least 6 months before enrollment. The final adjuvant radiotherapy, palliative radiotherapy (such as radiotherapy for bone metastases), and endocrine therapy should be completed at least 3 weeks before enrollment. For palliative radiotherapy of central nervous system (CNS) diseases, washout is allowed for one week.\n5. Recurrent endometrial cancer or advanced endometrial cancer that are not suitable for local treatment (including those with extensive abdominal and pelvic lesions, distant metastases, and those who cannot tolerate radiotherapy or surgery, if it is estimated that patients who may achieve surgery or radiotherapy after treatment are not suitable for enrollment).\n6. Prior antiangiogenic therapy is permitted.\n7. Signed Informed Consent Form (ICF).\n8. Provide tumor tissue samples fixed in formalin and embedded in paraffin for pathological examination\n9. In patients with measurable disease, lesions are defined and monitored by RECIST v1.1.\n10. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n11. Has adequate organ function as defined by the following criteria:\n\n1\\) Blood routine examination standards to meet: (no blood transfusion within 14 days)：\n\n* Hemoglobin of ≥90 g\u002FL, white blood cell (WBC) ≥3×109\u002FL, absolute neutrophil count (ANC) ≥1.5×109\u002FL, platelets ≥100 ×109\u002FL 2) Biochemical examination should meet the following criteria：\n* Total bilirubin ≤ 1.5 × upper limit of normal (ULN)\n* Aspartate aminotransferase (AST)\u002Falanine aminotransferase (ALT) ≤ 2.5 × ULN (however, patients with known liver metastasis who have AST or ALT level ≤ 5 × ULN may be enrolled)\n* Serum creatinine ≤ 1.5 × ULN 3) Urine protein ≤(++) , or 24-hour urine protein quantification less than 1 g; 4) International standard ratio (INR) and activated partial thromboplastin time ≤1.5 uln (unless anticoagulant therapy is used because of disease) ; 12. Adverse events from any previous treatment, except for symptomatic stable sensory neuropathy or alopecia ≤ CTCAE Grade 2, have returned to ≤ CTCAE grade 1 or baseline, except anemia; 13. Women of childbearing potential should have a negative serum or urine pregnancy test prior to receiving the first dose of study treatment; and should be willing to use one acceptable contraception (i.e., oral contraceptives, condoms, intrauterine devices \\[IUDs\\]) throughout the period of taking study treatment and for at least 3 months after the last dose of study drug(s).\n\n  14\\. Life expectancy exceeds 3 months.\n\nExclusion Criteria:\n\n1. Other malignant tumors in the past (within 5 years) or at the same time, excluding cured local tumors (such as basal cell skin cancer, squamous cell skin cancer, superficial bladder cancer, cervical carcinoma in situ, breast carcinoma in situ, etc.) and breast cancer and thyroid cancer that have no recurrence more than 3 years after the completion of radical surgery.\n2. Had received immunotherapy in the past, it includes immune checkpoint inhibitors (such as anti-PD-1 antibody, anti-PD-L1 antibody, anti-CTLA-4 antibody, etc.) , immune checkpoint agonists (such as ICOS, CD40, CD137, GITR, OX40 antibody, etc.) , immune cell therapy, etc. Such subjects may be admitted with the consent of the sponsor.\n3. Has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.\n4. Previous history of immunodeficiency; HIV antibody positive; Current long-term use of systemic corticosteroids or other immunosuppressants\n5. Subjects who are known to have active pulmonary tuberculosis (TB) and are suspected to have active TB need to undergo clinical examination to exclude them; Known active syphilis infection.\n6. Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.\n7. Previous history of non-infectious pneumonia\u002Finterstitial lung disease requiring systemic glucocorticoid treatment or current presence of non-infectious pneumonia.\n8. Serious infections occur within 4 weeks before the first administration, including but not limited to comorbidities, sepsis, or severe pneumonia that require hospitalization; Active infections (excluding antiviral treatment for hepatitis B or C) that have received systemic anti-infective treatment within two weeks prior to the first administration.\n9. Untreated subjects with active hepatitis B (HBSAg positive and HBV-DNA above 1000 copies\u002Fml (200 IU\u002Fml) or above the lower limit of detection, whichever is higher), for subjects with Hepatitis B, anti-HBV therapy was required during study treatment; subjects with active hepatitis C (HCV antibody positive and HCV-RNA levels above the lower limit of detection) .\n10. Those who had a major surgical procedure or major trauma within 30 days before the first dose, or who had a major surgical plan within 30 days after the first dose (at the investigator's discretion); Minor local procedures (excluding central venous catheterization via peripheral venipuncture and implantable venous accessport) were performed within 3 days before the first dose.\n11. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures.\n12. There are currently uncontrolled comorbidities, including but not limited to symptomatic congestive heart failure (grade 2 and above according to the New York Heart Association functional classification), unstable angina, acute myocardial ischemia, poorly controlled arrhythmia, decompensated liver cirrhosis, nephrotic syndrome, uncontrolled metabolic disorders, severe active peptic ulcer disease or gastritis, Mental illness\u002Fsocial status that may limit subjects' compliance with research requirements or affect their ability to provide written informed consent.\n13. Previous history of myocarditis, cardiomyopathy, and malignant arrhythmia. Unstable angina, myocardial infarction, congestive heart failure, or vascular disease requiring hospitalization (such as aortic aneurysm at risk of rupture), or other cardiac impairment (such as poorly controlled arrhythmias, myocardial ischemia) that may affect study drug safety evaluation within 12 months prior to first administration of study drug; A history of esophageal Gastric varices, severe ulcers, unhealed wounds, gastrointestinal perforation, abdominal fistula, tumor-related gastrointestinal obstruction, intra-abdominal abscess, or acute gastrointestinal bleeding in the 6 months before the first dose; Any arterial thromboembolic event, NCI CTCAE version 5.0 Grade 3 or higher, venous thromboembolism, transient cerebral ischemia, cerebrovascular accident, Hypertensive crisis, or hypertensive encephalopathy, occurred within 6 months before the first dose; Acute exacerbation of chronic obstructive pulmonary disease within 1 month of first dose\n14. A history of incurable abdominal fistula or gastrointestinal perforation; During the screening period, imaging revealed obvious tumor invasion of the intestinal wall.\n15. During screening, imaging or clinical findings of gastrointestinal obstruction, including incomplete obstruction.\n16. Previous history of severe bleeding or coagulation disorders; during screening, imaging showed that the neoplasm surrounded major blood vessels or had obvious necrosis and cavitation, and the investigators believed that participation in the study might increase risk of bleeding.\n17. Toxicities from previous antitumour therapy did not resolve, defined as toxicities that did not return to grade 0 or 1 of NCI CTCAE version 5.0, or levels specified in the inclusion\u002Fexclusion criteria; Except for alopecia and sequelae of neurotoxicity related to previous platinum therapy. For subjects who experienced irreversible toxicity and are expected to not worsen after the administration of the study drug (such as hearing loss), as well as subjects who have long-term toxicity caused by radiotherapy and cannot be restored according to the judgment of the researcher, if the researcher evaluates that the subject may benefit from the study treatment, they are allowed to be included in the study.\n18. Has received a live virus vaccine within 30 days prior to first administration of study drug or plan to be administered during the study period.\n19. Known allergy to any component of any investigational drug, known history of severe hypersensitivity to other monoclonal antibody.\n20. Known history of mental illness, substance abuse, alcohol, or drug abuse.\n21. Is pregnant, breastfeeding women.\n22. Any prior or current disease, treatment, or laboratory test abnormality that may confound the study endpoints, interfere with subjects' full participation in the study, or may not be in their best interest to participate in this study.\n23. Local or systemic diseases caused by non-malignant tumors, or diseases or symptoms secondary to tumors, which can lead to higher medical risk and\u002For uncertainty in survival evaluation, such as tumor like leukemia reactions (white blood cell count\\>20 × 109\u002FL), symptoms of cachexia (known to have lost more than 10% of body weight in the 3 months before screening), etc.",{"count":295,"type":20},45,[75],"This is an open-label, multi-center Phase II study of cadonilimab (AK104) combined with chemotherapy in patients with recurrent or advanced endometrial cancer. The primary objective is to evaluate objective response rate of cadonilimab plus chemotherapy.",[110,34],[110,300,301,302,303],"Immune Checkpoint Inhibitors (ICIs)","Anti-PD-1\u002FCTLA4 bi-specific antibody","Antiangiogenic agents","Chemotherapy","2024-01-20",{"date":306,"type":54},"2024-01-23",{"date":308,"type":20},"2024-02-01",{"date":310,"type":20},"2026-10-31",{"name":312,"class":313},"Fujian Cancer Hospital","OTHER_GOV"]